USPTO published patent application US20260091037A1 for sepiapterin compositions and methods of treating BH4-related disorders. The application (No. 19206193) claims compositions including sepiapterin or pharmaceutically acceptable salts thereof, and methods resulting in increased plasma, CSF, and/or brain exposure of sepiapterin. Inventors are Neil Smith and Jonathan Reis.

This is a routine patent application publication with no immediate compliance obligations. Pharmaceutical companies and researchers developing BH4-related disorder treatments may wish to review the claims for potential freedom-to-operate concerns. Patent applications are informational publications only; they do not grant enforceable rights until issued as patents following examination.